A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer
Interventions: DRUG: Talazoparib|DRUG: Atezolizumab|RADIATION: Radiation
Sponsor: Mylin A. Torres, MD
Collaborators: Genentech, Inc.|Pfizer|Emory University